FRANKFURT (Reuters) - Long-serving AstraZeneca boss Pascal Soriot said on Friday he expects to work with the new chairman-designate of the London-listed drugmaker, who will take over in 2023, for many years to come, suggesting he is not ready to retire.
The company said on Friday that Michel Demare will take over from outgoing Chairman Leif Johansson, who, like Soriot, has been in his leadership position for about a decade.
"Michel and I will be working together and forming an excellent team for the many years to come," Soriot said on an analyst call after the company released its quarterly results.
(Reporting by Ludwig Burger and Natalie Grover; editing by Jason Neely)
Pascal Claude Roland Soriot (born 23 May 1959) is the Chief Executive of the Anglo-Swedish pharmaceutical multinational company AstraZeneca, and has been since October 2012.
Early life
He studied Veterinary Medicine at university (École nationale vétérinaire d'Alfort at Maisons-Alfort in south-east Paris). as a salesman, where he lived in Australia.
AstraZeneca
On 28 August 2012 he was named as the new Chief Executive of AstraZeneca, the world's fifth largest pharmaceutical company, when aged 53. He took up the post on 1 October 2012.
Personal life
He is married with two children and one grandchild.
| Linked companies | |
|---|---|
| ASTRAZENECA PLC | Chief Executive Officer |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Chairman |
